Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/70625
Título: JAK, an Oncokinase in Hematological Cancer
Autores/as: Recio Cruz, Carlota Pilar 
Aranda Tavío, Haidee Magdalena 
Guerra Rodríguez, Miguel Alfonso 
De Mirecki Garrido, Mercedes 
Martín Rodríguez, Patricia 
Guerra Hernández, Carlos Borja 
Fernández Pérez, Leandro Fco 
Clasificación UNESCO: 320101 Oncología
Palabras clave: Blood cancer
Hematological tumor
JAK
STAT
Mutation, et al.
Fecha de publicación: 2019
Editor/a: IntechOpen 
Proyectos: Desarrollo Preclínico de Nuevas Estructuras Bioactivas Moduladoras de Las Actividades Oncogénicas de Stat3/5 O de Los Receptores de Estrógenos 
Resumen: Janus kinases (JAKs) play an essential role in the regulation of cytokine signaling. They control cell survival, proliferation, differentiation, immune response, and hematopoiesis. Deregulation of JAK signaling has been associated to the pathogenesis of numerous immune-inflammatory diseases, hematological malignancies, and solid tumors. Thus, JAK proteins have emerged as attractive therapeutic targets in the last decade. The discovery of the gain-of-function JAK2 mutation (JAK2 V617F) as the main cause of polycythemia vera—a chronic myeloproliferative syndrome—led to the development of the JAK inhibitor ruxolitinib. This key finding opened the door to the search for new therapeutic agents able to suppress the constitutive activation of JAK signaling in hematological cancers and other tumors. However, given the conserved nature of the kinase domain among JAK family members, and the interrelated roles of JAK kinases in many physiological processes, including hematopoiesis and immunity, the broad usage of JAK inhibitors in hematology is challenged by their narrow therapeutic window. Novel therapies are, therefore, needed. This chapter focuses on the understanding of the complex signaling of JAK proteins in cancerous cells, the various JAK aberrations implicated in myeloproliferative neoplasms, leukemia, and lymphoma, and the clinically available JAK inhibitors in cancer therapy.
URI: http://hdl.handle.net/10553/70625
ISBN: 978-1-78984-809-0
DOI: 10.5772/intechopen.84177
Fuente: Tyrosine Kinases as Druggable Targets in Cancer / Editado por Huan Ren
URL: https://www.intechopen.com/books/tyrosine-kinases-as-druggable-targets-in-cancer/jak-an-oncokinase-in-hematological-cancer
Colección:Capítulo de libro
Vista completa

Visitas

128
actualizado el 04-feb-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.